The cohort was 70% male, median age 59, the majority having hepat

The cohort was 70% male, median age 59, the majority having hepatitis C or alcohol-related cirrhosis (66%), high MELD (median 25) and a median follow-up of 45 days from SBP diagnosis. Nearly all were treated with conventionally dosed intravenous albumin (87%) and antibiotics (100%, 3rd-generation cephalosporin in 67%), reflecting a highly standardized treatment approach at our institution. Sixty-three

patients (34%) died and 5 underwent liver transplantation within 30 days of SBP diagnosis. Initial treatment failed in 26%, revealing the number needed to retap to identify treatment failure as 4. On multivariate analysis, peripheral white blood cell count (WBC)>11 × 103 cells/μL was associated with treatment failure (2.5; 1.15-5.52; p=0.02) whereas proton-pump inhibitor (PPI) use was inversely associated with treatment failure (0.42; 0.18-0.99; p=0.05). Individuals with treatment failure were 5-times more likely to have antibiotics broadened than those without failure (p<0.01). this website Conclusion: The number needed to retap to identify a single initial treatment failure was 4, suggesting good utility of repeat diagnostic paracentesis in patients with SBP. Peripheral WBC >11 × 103 cells/μL is associated with treatment failure and may identify a cohort of patients most likely to benefit from retap.

Individuals with treatment failure are 5-times more likely to have antibiotics broadened, which may have an impact on mortality. Additional cost-effectiveness analysis is required to determine if retap is of health care value. The possible protective effect of BI 6727 in vivo PPI use on treatment failure is unclear as acid-suppression therapy has been positively associated with SBP. Disclosures: Thomas D. Schiano – Advisory Committees or Review Panels: vertex, salix, merck, gilead, pfizer; Grant/Research Support: massbiologics, itherx The following people have nothing to disclose: Aparna Goel, Mollie A. Biewald, Gopi Patel, Shirish Huprikar, Gene Y. Im Introduction: Decreased IGF-1 serum levels have been reported

in patients with cirrhosis and seem to correlate with hepatic dysfunction intensity. However, data about its prognostic significance is still lacking. We sought to investigate the relationship between serum IGF-1 levels and short-term prognosis in patients admitted medchemexpress for acute decompensation of cirrhosis. Methods: In this prospective cohort study, patients admitted in the emergency department were followed during their hospital stay and 90-day mortality was evaluated by phone call, in case of hospital discharge. All subjects underwent laboratory evaluation at admission. The acute-on-chronic liver failure (ACLF) criteria were applied according to the EASL-CLIF Consortium definition. Twenty-one patients were also evaluated in the outpatient clinic after discharge and were compared in two moments (inpa-tient and outpatient evaluation). Results: Between December 2011 and November 2013, 103 patients were included, with a mean age of 54.2 ± 11.

Comments are closed.